Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

BACKGROUND: Although it is accepted that metastatic colorectal cancers (mCRCs) that carry activating mutations in KRAS are unresponsive to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, a significant fraction of KRAS wild-type (wt) mCRCs are also unresponsive to anti-EGFR therap...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Baker, J B, Dutta, D, Watson, D, Maddala, T, Munneke, B M, Shak, S, Rowinsky, E K, Xu, L-A, Harbison, C T, Clark, E A, Mauro, D J, Khambata-Ford, S
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2011
Matèries:
Molecular Diagnostics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049558/
https://ncbi.nlm.nih.gov/pubmed/21206494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6606054
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars